Ind-Swift Limited was incorporated as a public limited company on June 6, 1986 under the Companies Act 1956.It is the flagship company of India based Ind Swift Group. Ind-Swift Limited is a north India based pharmaceutical company.

Ind Swift Group is a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore.

Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, ointments, injectables, liquids & dry syrup (all latest formulations with a marketing network.

Business areas of the company are:

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include the following:Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence

The company is also in health Publications- With the maiden issue in September, 2002; Ind-Swift’s Health Publication TRENDZ brings the latest in medical field to the medical fraternity. Routinely published four times a year, each issue of TRENDZ is devoted to important contemporary healthcare issues and medical issues of a particular specialty.

Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and researchers.

 * A well accepted expertise in NDDS, in India and the world over.
 * A US patent for Clarie OD, with a market size of $300 million.
 * Another patent for Fexofenadine ODT with a market size of $2.5 billion.
 * Development of 10 new molecules with a market size of $6 billion.

Ind Swift’s efforts and achievements in taste masking of macrolides was India's first and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.

Ind Swift has radianced up in infrastructures business in the name and style of “Ind Swift Infrastructures and developers Ltd, and has come up with a multi crore project named “Regalia Towers”, of course a society with 2 bedroom /3 bedroom flats and penthouses owing a mystique which is exemplary in itself which not only reflects a diversified transformative spell to infrastructures front but a unique state of art with the best of specifications also. In infrastructures, Ind Swift plans to be emergent with motels & Resorts project in the upcoming phases.

Ind-Swift Ltd.

Biofil Chemicals & Pharmaceuticals Ltd.

Vineet Laboratories Ltd.

Lasa Supergenerics Ltd.

Vivimed Labs Ltd.

Vaishali Pharma Ltd.

Mangalam Drugs And Organics Ltd.

SMS Lifesciences India Ltd.

Ortin Laboratories Ltd.

Parenteral Drugs (India) Ltd.

Bal Pharma Ltd.

Krebs Biochemicals & Industries Ltd.

Alpa Laboratories Ltd.

Bafna Pharmaceuticals Ltd.

Brooks Laboratories Ltd.

Open Price	18.35	Volume	1
Prev. Close	18.35

Performance